Regulatory Affairs - FarmavitaR - Regulatory affairs network

Regulatory Affairs

Open Source Pharmaceuticals - New Business Model

Friday, 12 January 2007 23:43 Regulatory Affairs - Other issues

Open Source Pharmaceuticals - New Business Model

"Open source" as applied to culture defines a culture in which intellectual property is made generally available. Participants in such a culture are able to improve and modify those products and redistribute them back into the community. Farmavita.Net is now inviting proposals for "open source pharmaceutical projects". Web 2.0 based software available at www.farmavita.net is allowing knowledge sharing and management of complex international, multi-center projects.

CEE Sourcing

Monday, 17 July 2006 23:49 Zdravko Mauko Regulatory Affairs - Europe not-EU

Central European markets to source drugs from India

GIREESH CHANDRA PRASAD; TIMES NEWS NETWORK [ MONDAY, JULY 17, 2006 01:57:27 AM]

NEW DELHI: Central European countries with relatively smaller pharmaceutical markets are now courting Indian drug makers to cut down the huge subsidies they provide to their healthcare system.

CEFTA

Sunday, 12 March 2006 23:58 Zdravko Mauko Regulatory Affairs - Europe not-EU

Central European Free Trade Agreement

The Central European Free Trade Agreement (CEFTA) is a trade agreement between Romania, Bulgaria, Croatia and the Republic of Macedonia. Former members are Poland, the Czech Republic, Slovakia, Hungary and Slovenia.

Patent Expiry Dates

Wednesday, 01 March 2006 03:03 Jesse Tale Regulatory Affairs - Other issues

How to Calculate Standard Patent Expiry Dates and Data Exclusivity in Key Territories

Use this handy guide to navigate the calculation of patent expiry dates in US, Canada, Germany, Spain, France, United Kingdom and Australia, and also data exclusivity in the US, Canada, Europe and Australia.

Evergreening

Thursday, 23 February 2006 21:41 Regulatory Affairs - Other issues

Evergreening through Patent Strategies

One form of evergreening occurs when the originator manufacturer “stockpiles” patent protection by obtaining separate 20-year patents on multiple attributes of a single product. But many other evergreening strategies exist ...

Information provided by European Generic Association.